A Phase 3 Randomized, Open-label Study of RinatabartSesutecan (Rina-S) versus Treatment of Investigator's Choice (IC) in Patients with Platinum Resistant Ovarian Cancer
Clinical Trial Grant
Awarded By
Genmab US, Inc.
Start Date
February 11, 2025
End Date
February 3, 2030
Awarded By
Genmab US, Inc.
Start Date
February 11, 2025
End Date
February 3, 2030